JP2005524713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005524713A5 JP2005524713A5 JP2004502920A JP2004502920A JP2005524713A5 JP 2005524713 A5 JP2005524713 A5 JP 2005524713A5 JP 2004502920 A JP2004502920 A JP 2004502920A JP 2004502920 A JP2004502920 A JP 2004502920A JP 2005524713 A5 JP2005524713 A5 JP 2005524713A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- diazabicyclo
- heptane
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 230000009429 distress Effects 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- WPUUTPPTQDJKRV-QWRGUYRKSA-N (1s,4s)-2-(6-thiophen-3-ylpyrazin-2-yl)-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(N=1)=CN=CC=1C=1C=CSC=1 WPUUTPPTQDJKRV-QWRGUYRKSA-N 0.000 claims 1
- XTNOLIRTPSQXSZ-QWRGUYRKSA-N (1s,4s)-2-(6-thiophen-3-ylpyridazin-3-yl)-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(N=N1)=CC=C1C=1C=CSC=1 XTNOLIRTPSQXSZ-QWRGUYRKSA-N 0.000 claims 1
- LFPZJAIOTPCCSD-RYUDHWBXSA-N (1s,4s)-5-methyl-2-(6-thiophen-3-ylpyridazin-3-yl)-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C=1C=CSC=1 LFPZJAIOTPCCSD-RYUDHWBXSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000022372 Reading disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040981 Sleep attacks Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200692 | 2002-05-07 | ||
| DKPA200201739 | 2002-11-11 | ||
| PCT/DK2003/000295 WO2003094831A2 (en) | 2002-05-07 | 2003-05-06 | Novel diazabicyclic biaryl derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005524713A JP2005524713A (ja) | 2005-08-18 |
| JP2005524713A5 true JP2005524713A5 (enExample) | 2006-06-15 |
Family
ID=29421783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004502920A Pending JP2005524713A (ja) | 2002-05-07 | 2003-05-06 | 新規ジアザビシクロビアリール誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7300933B2 (enExample) |
| EP (1) | EP1506200B1 (enExample) |
| JP (1) | JP2005524713A (enExample) |
| CN (1) | CN1653068A (enExample) |
| AT (1) | ATE348831T1 (enExample) |
| AU (1) | AU2003223927B2 (enExample) |
| CA (1) | CA2480488A1 (enExample) |
| DE (1) | DE60310548T2 (enExample) |
| DK (1) | DK1506200T3 (enExample) |
| MX (1) | MXPA04010966A (enExample) |
| NZ (1) | NZ535642A (enExample) |
| WO (1) | WO2003094831A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| TW200534855A (en) * | 2004-01-13 | 2005-11-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| US7582631B2 (en) | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005087236A1 (en) * | 2004-03-11 | 2005-09-22 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| WO2005094251A2 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3muscarinic acetylcholine receptor antagonists |
| JP4931823B2 (ja) | 2004-10-18 | 2012-05-16 | アムジエン・インコーポレーテツド | チアジアゾール化合物及び使用方法 |
| JP2008530172A (ja) * | 2005-02-16 | 2008-08-07 | ノイロサーチ アクティーゼルスカブ | ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用 |
| EP1866314B1 (en) | 2005-02-16 | 2010-09-15 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| DE602006019561D1 (de) * | 2005-02-16 | 2011-02-24 | Neurosearch As | Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren |
| US7897766B2 (en) | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
| CA2632642A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| JP2011500625A (ja) * | 2007-10-18 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリ置換された１，２，４−トリアゾール |
| AR070936A1 (es) | 2008-03-19 | 2010-05-12 | Janssen Pharmaceutica Nv | 1,2,4 -triazoles trisustituidos |
| JP5486591B2 (ja) | 2008-05-09 | 2014-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アセチルコリン受容体モジュレーターとしての三置換ピラゾール |
| AU2010328419A1 (en) * | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| TWI519532B (zh) | 2010-05-17 | 2016-02-01 | 艾維沃製藥公司 | （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體 |
| EP2619205B1 (en) | 2010-09-23 | 2017-05-17 | AbbVie Bahamas Ltd. | Monohydrate of an azaadamantane derivative |
| RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| US9040712B2 (en) * | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| JP6094842B2 (ja) * | 2013-10-29 | 2017-03-15 | エルジー・ケム・リミテッド | ゲルポリマー電解質及びこれを含むリチウム二次電池 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| FR2786769B1 (fr) * | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
| EP1147112B1 (en) | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| EP1289996B1 (en) * | 2000-05-25 | 2005-04-06 | Targacept, Inc. | Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands |
-
2003
- 2003-05-06 MX MXPA04010966A patent/MXPA04010966A/es active IP Right Grant
- 2003-05-06 DE DE60310548T patent/DE60310548T2/de not_active Expired - Lifetime
- 2003-05-06 CA CA002480488A patent/CA2480488A1/en not_active Abandoned
- 2003-05-06 DK DK03720288T patent/DK1506200T3/da active
- 2003-05-06 AU AU2003223927A patent/AU2003223927B2/en not_active Ceased
- 2003-05-06 JP JP2004502920A patent/JP2005524713A/ja active Pending
- 2003-05-06 NZ NZ535642A patent/NZ535642A/en not_active IP Right Cessation
- 2003-05-06 EP EP03720288A patent/EP1506200B1/en not_active Expired - Lifetime
- 2003-05-06 WO PCT/DK2003/000295 patent/WO2003094831A2/en not_active Ceased
- 2003-05-06 US US10/513,398 patent/US7300933B2/en not_active Expired - Fee Related
- 2003-05-06 CN CNA03810198XA patent/CN1653068A/zh active Pending
- 2003-05-06 AT AT03720288T patent/ATE348831T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100513406C (zh) | 新的奎宁环衍生物及其用途 | |
| EP1427411B1 (en) | (-)-1-(3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor | |
| JP2005538187A5 (enExample) | ||
| JP2006508109A5 (enExample) | ||
| AU2003223927B2 (en) | Novel diazabicyclic biaryl derivatives | |
| ZA200609255B (en) | 1-aza--bicyclo[3.3.1] nonanes | |
| CA2389553A1 (en) | Heteroaryl-diazabicycloalkanes | |
| JP2006503062A5 (enExample) | ||
| JP2004538268A5 (enExample) | ||
| JP2006508109A (ja) | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 | |
| JP2005530814A5 (enExample) | ||
| JP2008530171A (ja) | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 | |
| JP4711391B2 (ja) | 新規１，４−ジアザビシクロアルカン誘導体及びその製造方法 | |
| EP1713809B1 (en) | Dimeric azacyclic compounds and their use | |
| JP2009537599A5 (enExample) | ||
| JP2009519282A (ja) | 精神病および神経変性障害の処置のための、ｎ−ＡＣｈＲのコリン作動性リガンドとしての（１−アザ−ビシクロ［３．３．１］ノン−４−イル）−［５−（１Ｈ−インドール−５−イル）−ヘテロアリール］−アミン | |
| JP2007520525A5 (enExample) | ||
| JP2005524712A5 (enExample) | ||
| CN1124266C (zh) | 氮杂环辛烷和庚烷衍生物、其制备方法和治疗用途 | |
| RU2010135037A (ru) | Новые производные, 1,4-диазабицикло[3.2.2]нонилоксадиазолил, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| US7750022B2 (en) | Quinuclidine derivatives and their pharmaceutical use | |
| CN101044144A (zh) | 作为胆碱能配体的新的二氮杂双环芳基衍生物 | |
| CN1331864C (zh) | 新型2,5－二氮杂二环[2.2.1]庚烷衍生物 | |
| JP2004529901A5 (enExample) | ||
| HK1073600A (en) | (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof and uses as a dopamine-reuptake inhibitor |